Phoenix Asia Holdings Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of April 2025 for Phoenix Asia Holdings Limited, a foreign private issuer. The report details the completion of the Company's initial public offering (IPO) and the commencement of trading on The Nasdaq Capital Market under the ticker symbol "PHOE".
Key Financial Metrics
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the capital raise:
- Shares Offered: 1,600,000 ordinary shares.
- Offering Price: $4.00 per share.
- Over-Allotment Option: Up to 240,000 additional shares (15% of the offering).
- Net Proceeds: Approximately $5.76 million after deducting underwriting discounts, fees, and estimated offering expenses.
Material Changes
The most significant material change is the Company's transition to a publicly traded entity. Key milestones include:
- April 24, 2025: Entered into an underwriting agreement with D. Boral Capital LLC and the registration statement was declared effective.
- April 25, 2025: Ordinary Shares commenced trading on The Nasdaq Capital Market.
- April 28, 2025: The Offering officially closed.
Outlook, Risks, and Unusual Items
Lock-Up Period: Officers, directors, and all shareholders have agreed to a 180-day lock-up period from the date of the final prospectus, restricting the sale or disposal of ordinary shares without underwriter consent.
Legal Disclosures: The Underwriting Agreement contains customary representations, warranties, and indemnification obligations. These are qualified in their entirety by reference to the agreement filed as Exhibit 1.1.
Unusual Items: The filing notes a discrepancy in the text regarding press release dates, stating "April 24, 2024" and "April 28, 2024" in the narrative, while the context and exhibit descriptions clearly indicate the year is 2025. The filing date is April 30, 2025.
Investor Verification Checklist
- Verify the final number of shares sold, including whether the 45-day over-allotment option was exercised.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification terms and termination provisions.
- Confirm the actual use of the $5.76 million in net proceeds as outlined in the final prospectus.
- Monitor the stock price performance on The Nasdaq Capital Market following the April 25, 2025 listing.
- Clarify the press release date discrepancy noted in the filing text versus the exhibit descriptions.